AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

LNTH · NASDAQ · Drug Manufacturers - Specialty & Generic

Lantheus (LNTH)

Commercializes PET radiodiagnostics and ultrasound-enhancing agents for prostate cancer, amyloid, and cardiac imaging.

$99.93

vs last close−0.07 (−0.07%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	320	354	370	394	379	391	373	378	384	407	377	388
Cost of revenue	120	124	118	138	137	143	135	137	162	166	146	146
Gross profit	200	230	252	256	242	249	238	241	222	241	231	242
	88	92	151	153	108	135	136	153	179	164	150	142
Research & development	14	17	48	61	24	35	36	45	48	47	39	38
	73	76	93	92	84	102	99	108	131	116	110	103
Selling & marketing	37	35	46	45	44	44	43	41	49	46	53	83
General & administrative	36	40	48	47	41	58	57	67	82	70	58	21
Other expenses	0	0	10	0	0	−2	0	0	0	0	0	0
Operating income	112	137	100	103	134	114	102	88	44	77	81	100
	48	1	71	−18	42	−115	−6	17	−1	−7	75	−6
Interest income	5	8	9	9	10	10	9	7	4	3	5	0
Interest expense	5	5	5	5	5	5	5	5	5	5	5	5
Other non-operating income	−53	−6	−76	13	−47	110	1	−21	−4	2	−80	1
Income before tax	160	138	171	84	176	−1	97	105	42	70	156	94
Income tax expense	28	35	40	22	45	11	24	26	15	16	38	19
Net income from continuing operations	132	103	131	62	131	−12	73	79	28	54	118	75
Net income	132	103	131	62	131	−12	73	79	28	54	118	75
EPS, basic	$1.93	$1.51	$1.91	$0.90	$1.89	−$0.17	$1.06	$1.15	$0.41	$0.82	$1.83	$1.15
EPS, diluted	$1.88	$1.47	$1.87	$0.88	$1.79	−$0.17	$1.02	$1.12	$0.41	$0.82	$1.80	$1.11
Weighted average shares, basic	68	68	69	69	69	69	69	69	67	66	65	65
Weighted average shares, diluted	70	70	70	71	73	69	71	70	68	66	66	68
EBITDA	180	158	192	104	198	22	115	123	68	98	184	115
Depreciation & amortization	15	15	15	15	17	17	14	13	20	23	23	17
EBIT	165	143	176	89	181	4	101	109	47	75	161	99